Skip to main content

Table 1 Summary of the cervical cancer study characteristics

From: Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis

   Population and Intervention   Study groups Outcomes
First author, publication year Study
Design
Comments Patients
(N)
Type of ovarian transposition Follow up (Median, range in months) Surgery
Only
Surgery + BR Surgery + 
EBRT ± BR
Retained
Function
Cyst Metastasis
Hodel [36]
1982
Retrospective Stage 1B cervical cancer 7 Open NR 0 1 6 5 1 0
Husseinzadeh [17] 1984 Prospective 15/22 from surgery only group were included for which FSH levels were available 19 Open NR 15 0 4 17 0 0
Ploch [18]
1988
Prospective Focus on ovarian function only, additional analysis of location of transposed ovaries 22 Lap 13 (2–23) 5 5 12 15 0 0
Owens [19]
1989
Retrospective All but three patients had early-stage cervical cancer, one patient had unilateral OT 14 Open 18 6 0 8 13 0 0
Chambers [21]
1990
Retrospective Stage 1 cervical cancer,
description of lateral OT
25 Open (sc) 14 (2–23) 25 0 0 22 6 0
Van Beurden [39] 1990 Retrospective FSH levels were available for 6 patients 6 Open 23 (10–36) 0 0 6 1 0 0
Chambers [21]
1991
Retrospective Stage 1 cervical cancer, ovarian preservation causally related to estimated scattered dose to ovaries 38 Open 35 24 0 14 27 7 0
Anderson [22]
1993
Retrospective Comparison with a non- transposition group 82 Open / Lap 44 58 0 24 51 38 1
Bidzinski [23]
1993
Prospective Stage 1 cervical cancer, ultrasound examination showed distinct reduction of transposed ovary echo structure in 91% cases 48 Open 41 (10–72) 9 24 15 45 0 0
Feeney [24]
1995
Retrospective Ovarian function is reserved only in 50% of patients with postoperative BR 132 Lap 24 104 0 28 115 4 2
Clough [6]
1996
Prospective Unilateral OT, success rate 100% in patients younger than 40 years old 17 Open 23.6 (12–33) 0 11 6 15 0 0
Covens [37]
1996
Retrospective Patients with 1B cervical cancer prior to RT 3 Open 32 0 0 3 2 0 0
Fujiwara [25]
1997
Retrospective Description of a new technique for OT 27 Open (sc) 27 (10–44) 25 1 1 26 18 0
Morice
1998
Prospective Only 14/ 24 were included as they were repeated in other paper published by the same author 14 Lap 6 0 10 4 11 0 0
Morice [26]
2000
Prospective 95/107 patients were included; 12 patients were lost on follow up 95 Lap 31 (10–56) 11 59 25 79 25 1
Buekers [27]
2001
Retrospective Stage 1 cervical cancer, 27 women had unilateral oophorectomy for intraoperative suspicion or vascular compromise 80 Open 87 (43–126) 54 0 26 64 0 0
Olejek [28]
2001
Prospective Significance in ovarian preservation between RT and non-RT groups 44 Open 60 19 6 19 31 3 0
Yamamoto [11]
2001
Prospective Regression analysis of risk factors for ovarian metastases 56 Open 12 30 0 26 50 0 0
Nagao [29]
2006
Retrospective Subcutaneous fat OT, direct comparison to a non-transposition group 27 Open (sc) 65 22 0 5 25 3 0
Pahisa [30]
2008
Prospective 24/28 patients with 1b1 cervical cancer were included for which follow up was available 24 Open / Lap 44 13 6 5 20 2 0
Al-Badawi [31]
2010
Retrospective Stage 1–2 cervical cancer, 11/14 women were < 40 years old 15 Lap 33 0 0 15 11 0 0
Han [38]
2011
Retrospective 19/29 patients with cervical cancer for which FSH was available 19 Open / Lap 17.2 0 0 19 11 3 0
Hwang [32]
2012
Retrospective 39/53 patients were included; 14 patients were lost on follow up or FSH not available 39 Open / Lap 39.8 8 0 31 18 1 0
Zhao [43] 2013 Retrospective Stage 1–2 cervical cancer, risk factors for ovarian metastases reported 105 Open N/R 105 0 0 - - 2
Shou [40]
2015
Retrospective 6/26 patients with IIB-IIIB cervical cancer for which follow-up was available 26 Lap N/R 0 0 26 18 - 0
Du Z [33]
2017
Retrospective 52/86 patients had concurrent chemotherapy; the relationship between ovarian function and ovarian limited dose (IMRT) in radiotherapy was evaluated 86 Open 6 21 0 13 34 - -
Swift [34]
2018
Retrospective 9 patients with stage 1B1-2A cervical cancer, those who had chemoradiotherapy were excluded, description of a novel technique of laparoscopic lateral OT 6 lap 8–103 2 0 4 6 1 0
Hoeckman [35] 2018 Retrospective 23 patients with cervical carcinoma 23 Open/lap 34.5 (1.5–96) 0 0 23 16 0 0
Lv [41]
2019
Retrospective 77/150 patients,45 years who had complete follow-up, the association between the location of the transposed ovary and the ovarian dose was examined 77 Open 12 0 0 77 56 0 0
Yin L [42] 2019 Retrospective 105/118 patients received limited dose IMRT 118 Open 12 0 0 118 41 - 0
Total    1160   2–126 449 132 579 819 125 4